The Food and Drug Administration on Tuesday instructed Eli Lilly and Novo Nordisk to remove warnings about the risk of suicidal thoughts and behavior from the labels of their GLP-1 weight-loss drugs, such as Wegovy, Saxenda, and Zepbound.
FDA Calls for Removal of Suicide Warnings from Weight-Loss Drugs